- Home
- ANGH vs NRSN Comparison
ANGH vs NRSN Comparison
Compare ANGH & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGH | NRSN |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United Arab Emirates | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 26.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANGH | NRSN |
|---|---|---|
| Price | $2.88 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 2.4M | 307.5K |
| Earning Date | 04-30-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $96,736,848.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 85.06 | N/A |
| 52 Week Low | $2.25 | $0.68 |
| 52 Week High | $7.70 | $2.60 |
Technical Indicators
Market Signals| Indicator | ANGH | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 50.13 |
| Support Level | $2.57 | $0.92 |
| Resistance Level | $3.72 | $1.08 |
| Average True Range (ATR) | 0.54 | 0.10 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 11.85 | 54.55 |
Price Performance
Historical ComparisonAbout ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.